BioHealth Innovation
If you are having trouble viewing this email, please click here

January 16, 2018

IP Strategies for Start-Ups – January 18th BHI 1:1 Office Hours with Experts

Are you worried about protecting your Intellectual Property? What about trademarks? How do you negotiate licenses? Have you thought through your patent strategy? How do you manage patents globally?

Learn about these issues and more from experts at Wilson Sonsini Goodrich & Rosati who will provide advice through 1:1 sessions at the Montgomery County Innovation Center in Rockville this Thursday, January 18th.

Preregistration by noon tomorrow, 1/17, REQUIRED(Sessions filled on a first come-first served basis.)

Rockville Innovation Center (155 Gibbs Street, Rockville)

1:1 Office Hours - 9:10 a.m.-12:00 p.m.

9:10-9:40 a.m.  Booked

9:45-10:15 a.m. Booked

10:20-10:50 a.m. Booked

10:55 - 11:25 a.m. Booked

11:30 - 12:00 p.m. Booked


1:10 - 1:40 p.m.  Booked

1:45 - 2:15 p.m. RSVP

2:20 - 3:10 p.m. RSVP

3:15 - 3:45 p.m. RSVP 

Contact us for more information

Read More

REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy Nasdaq:AVXS

REGENXBIO Inc. (Nasdaq:RGNX) and AveXis, Inc. (Nasdaq:AVXS) today announced that they have entered into an amendment which expands upon the exclusive, worldwide license agreement they entered into in March 2014 (2014 License Agreement) for the development and commercialization of products to treat spinal muscular atrophy (SMA). AveXis’ initial proprietary gene therapy candidate, AVXS-101, is in a pivotal trial for the treatment of SMA Type 1, and a Phase 1 trial for SMA Type 2. AVXS-101 uses REGENXBIO’s NAV AAV9 vector.

Read More

Qiagen and DiaSorin partner on tuberculosis testing

Qiagen has announced a new partnership with DiaSorin that will allow the companies to offer new automated tuberculosis detection capabilities for their customers.

Read More

Voluntis and WellDoc Announce Partnership to Combine Diabetes Digital Therapeutic Offerings

Voluntis and WellDoc®, two of the industry’s leading digital therapeutics companies, announced today a commercial agreement aimed at combining Voluntis’ insulin titration technology with WellDoc’s extensive digital coaching platform to create a holistic digital diabetes management solution for patients, providers, health systems and health plans.

Read More

Machfu Announces Release of MACH-3 Industrial Internet of Things Platform and Gateway | Business Wire

Machfu, an Industrial Internet of Things (IIoT) technology company, announced today the release of its MACH-3 IIoT Gateway, a device allowing companies in energy, water, oil and gas as well as other industrial segments to seamlessly connect legacy infrastructure to cloud based IoT and existing SCADA systems. The product was designed to both simplify the connection and management of devices as well as provide a secure and easily customizable application framework to process and manage data at the network edge. The versatile functionalities of the MACH-3 IIoT Gateway will be demonstrated at the 2018 DistribuTECH show, January 22-25 in San Antonio, Texas.

Read More

D.C.-area technology investment soared in 2017, but early-stage firms still struggle - The Washington Post

Venture capitalists poured $1.55 billion into D.C. area technology start-ups last year, an industry report found, as a handful of so-called megadeals propelled the region to a six-year high for technology investing in 2017.

Read More

TAI Diagnostics Raises $10M, Inks Deal With United Therapeutics - Xconomy

TAI Diagnostics said earlier this week that it had closed a $10 million round of funding and forged a new partnership with United Therapeutics (NASDAQ: UTHR).

Read More

EU Approves AstraZeneca’s Respiratory Biologic | BioPharm International

AstraZeneca and MedImmune, its biologics research and development arm, announced that the European Commission (EC) has approved the companies’ respiratory biologic, benralizumab, as an add-on maintenance treatment for adults with severe eosinophilic asthma that is inadequately controlled despite high-dose inhaled corticosteroids, plus long-acting b-agonists.

Read More

PepVax Announces Completion of Efficacy Study with Key Pre-Clinical Data to Validate PVX-009,

PepVax, Inc., an early-stage biotechnology company, announced today that it has successfully completed the efficacy study for its lead candidate, PVX-009. The Company is harnessing the power of the immune system to target a specific protein, MAGE A, in an effort to find a treatment for triple negative breast cancer (TNBC).

Read More

Apply to Trajectory Next- University of Maryland Graduate School

Trajectory Next will provide formalized support and guidance to companies to help them execute a pilot, establish traction, and improve their ability to attract and attain customers.

Read More

Key takeaways from the J.P. Morgan Healthcare Conference - MedCity News

It’s another year, and the annual J.P. Morgan Healthcare Conference, along with all the small and big events it has spawned, has concluded. San Franciscans have their city back from the money-seeking health entrepreneurs, the CEOs, their retinue, and the investor hordes.

Read More

Novavax veteran lines up as next president of Icon’s ClinicalRM | FierceBiotech

Icon has hired a retired colonel who is moving into the biotech sphere as new president of its subsidiary ClinicalRM. James Cummings, M.D., will lead the CRO’s unit, which helps provide research to a range of U.S. federal health agencies.

Read More

Precision For Medicine Expands Services In Europe, Announces Next Generation Biomarker Data Management And Translational Informatics Platform

Precision for Medicine, part of Precision Medicine Group, today announced it is expanding its biomarker data management and translational informatics services into Europe. The addition of a Geneva, Switzerland-based team of experts complements Precision's US offerings to provide clients with truly global translational research services. The Geneva team also gives Precision another European operational base, continuing Precision's active international expansion.

Read More

R&D Grants Available for Maryland’s Hi-Tech Entrepreneurs

Grants up to $1 million are available from the US-Israel Bi-national R&D (BIRD) Foundation to support new product development R&D, conducted as a joint project between American and Israeli companies. The grants are only to be repaid if the resulting technology successfully achieves sales in the market. BIRD's wide-ranging scope extends to Agriculture, Communications, Life Sciences, Electronics, Software, Homeland Security, Renewable and Alternative Energy and more. The Maryland/Israel Development Center (MIDC) coordinates the BIRD program for our state.

Read More

Alexandria Venture Investments Launches the Alexandria Seed Capital Platform, a Novel and

Alexandria Venture Investments, the strategic venture capital arm of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, today announced the formal launch of the Alexandria Seed Capital Platform, an innovative funding model that brings together leaders from across the life science community to catalyze seed-stage investment in the most promising life science startups.

Read More

Roche, GE to develop digital diagnostics platform - MarketWatch

Roche Holding AG (ROG.EB) said Monday that it has entered into a strategic partnership with GE Healthcare to jointly develop and market a digital clinical-decision support platform.

Read More

Pharma, biotech will repatriate billions thanks to Trump's tax bill, Alexandria Real Estate chair says | Fox Business

The pharma and biotech industry will send billions of dollars back to the United States as a result of President Donald Trump’s tax overhaul, Alexandria Real Estate (ARE) Chairman Joel Marcus said on Monday.

Read More

15 companies graduate from UMBC's bwtech, ready to grow on their own - Baltimore Business Journal

More than 110 companies have graduated since bwtech@UMBC began offering incubation services in 1989.

Read More

A dynamite year for VC - NVCA

Explore the infographic to discover key insights from the upcoming 4Q PitchBook-NVCA Venture Monitor. For a complete analysis of VC activity, sign up to receive the full report—we’ll send it to you as soon as it publishes on Jan. 17.

Read More

Lupin receives FDA approval for generic Tamiflu Capsules

Pharma Major Lupin announced that it has received final approval for its Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) from the United States Food and Drug Administration (FDA) to market a generic version of Hoffman-La Roche, Inc.’s Tamiflu Capsules, 30 mg, 45 mg, and 75 mg.

Read More

UMBC launches program to prep students for biotech careers in partnership with Montgomery College and The Universities at Shady Grove – UMBC NEWS

A new degree program developed jointly by UMBC and Montgomery College (MC), and soon to be offered at The Universities at Shady Grove (USG), will create opportunities for students of all backgrounds to pursue high-demand careers in the life sciences. The four-year Translational Life Science Technology (TLST) program, which leads to a bachelor of science degree from UMBC, will train students in the fundamentals of biochemistry, cell biology, epidemiology, statistics, lab instrumentation, and biochemical engineering, as well as give students opportunities to develop sought-after skills such as analytical thinking, teamwork, and data evaluation. The TLST program is accepting students now, and courses will begin in fall 2018.

Read More

Press release - KeyGene Licenses University of Wisconsin Sequence-Based Genotyping Patents - Keygene

KeyGene and the University of Wisconsin-Madison announced today that they have entered into a service license agreement to practice KeyGene’s patented Sequence Based Genotyping (SBG) methods. Under the agreement, UW-Madison, through its Biotechnology Center (UWBC), is licensed to offer SBG services in all species to research collaborators and clients worldwide.

Read More

Pfizer Halts Drug Research For Alzheimer's and Parkinson's Because It's Too Expensive [Updated]

Pfizer, one of the world’s largest drug companies, announced over the weekend that it would stop work on new drugs to fight Alzheimer’s disease and Parkinson’s disease. The reason? Pfizer believes that research on the two diseases doesn’t make sense financially.

Read More

Jackson Lab Wins $3.2M NIH Grant to Develop Epigenome Modification Tech - GenomeWeb

The Jackson Laboratory has been awarded a $3.2 million grant from the National Institutes of Health to develop an epigenome modification technology for studying gene regulation in biological processes and disease states.

Read More

The 10 Most Innovative Life Sciences Deals of 2017 – LAKE WHILLANS

In recent years, Lake Whillans has published extensively on the multifaceted interplay between the legal market and the life sciences industry, specifically identifying the most active and relevant law firms for life science companies.

Read More

GSK CEO Emma Walmsley on diversity in pharma - INSIDER

GlaxoSmithKline CEO Emma Walmsley made history in 2017, when she became the first woman to head up a major pharmaceutical company.

Read More

Cell Therapy Manufacturing: All Signs Point to Commercialization - GEN

Cell therapy is the delivery of living cells to treat, or potentially cure, a person’s disease. The transplantation of hematopoietic stem cells from a donor to a recipient to create bone marrow, for instance, is one well-established form of cell therapy.

Read More

Which drug patents expire in 2018? - MedCity News

To state the obvious: Drugs are increasingly complex and so are their patent lives.

Read More

Where Big Pharma Giants And Their Venture Arms Are Betting On Cancer Therapies

2018 is already seeing big deals in the cancer therapy space with Celgene’s recent buyout of Impact Biomedicines, which develops a key drug for treating complex cancers.

Other big pharma names like Pfizer, Novartis, and GlaxoSmithKline have also been active in the last 5 years with key investments to cancer startups as they make bets to avoid missing out on strengthening their cancer drug pipelines.

Read More

Venture Capital Funding Trends Report 2017


2017 was the second year that saw dollar funding top $70B, but deals declined for the third straight year, falling 4% from 2016 and reaching the lowest annual total since 2012.

Read More

CDC: Worst flu season in years - GlaxoSmithKline (NYSE:GSK) - Seeking Alpha

The entire continental U.S. is experiencing widespread flu right now, the first time in the 13 years of the current tracking system that that has happened, according to the CDC.

Read More

The Sad Story of How a DC Tech Incubator Fell Apart - Washingtonian

Once heralded as a centerpiece of DC’s tech scene, start-up incubator 1776 proved less revolutionary than its name.

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.